Search results for "Alcohol"

showing 10 items of 1798 documents

Interaction of alcohol intake and cofactors on the risk of cirrhosis.

2010

OBJECTIVE: Evaluation of the interaction between alcohol intake and cofactors [hepatitis B virus (HBV), hepatitis C virus (HCV), body mass index] and coffee consumption on the risk of cirrhosis. DESIGN: Seven hundred and forty-nine consecutive patients with chronic liver disease referring to units for liver or alcohol diseases in Italy during a 6-months period. Teetotalers were excluded. The odds ratios (OR) for cirrhosis were evaluated using chronic hepatitis cases as the control group. RESULTS: An alcohol intake of more than 3 units/day resulted associated with the likelihood of cirrhosis both in males (OR 4.3; 95% CI=2.5-7.3) and in females (OR 5.7; 95% CI=2.3-14.5). A multiplicative int…

AdultLiver CirrhosisMaleHepatitis B virusAlcohol Drinkingalcohol cirrhosis coffeeHepacivirusCoffeeRisk Assessmentcirrhosis coffeeBody Mass IndexNORisk FactorsOdds RatioHumansCIRRHOSISAgedHepatitis B Surface AntigensalcoholHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CItalyCase-Control StudiesDisease ProgressionRNA ViralFemale
researchProduct

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

2005

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCarcinoma HepatocellularCirrhosisalcohol abuseHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeRisk FactorsVirologyPrevalencemedicineHBVHumansAgedbusiness.industryIncidenceLiver DiseasesLiver NeoplasmsHepatitis CMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis CVirologyAlcoholismInfectious DiseasesItalyHepatocellular carcinomaChronic DiseaseHCVFemaleViral hepatitisbusiness
researchProduct

Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys

2019

Background: The information on the geographical characteristics of chronic liver diseases (CLD) in Italy is out-dated. Aim: To provide up-dated information on the geographical pattern of patients with CLD born in Italy. Methods: Patients with CLD were enrolled in two national surveys performed in 2001 and 2014, which prospectively recruited subjects aged ≥18 years referring to Italian liver units located throughout the country that apply a similar clinical approach and analytical methods. Results: The total number of patients enrolled was 11,676. Alcohol-related CLD was more frequently observed in northern/central areas (25.0% vs. 20.7%, p < .001), while HBV-related (15.4% vs. 13.3%, p =…

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesAlcohol; Chronic hepatitis; Geographical pattern; HBV; HCV; Liver cirrhosisLiver cirrhosiGeographical patternHepatitis B ChronicChronic hepatitisSurveys and QuestionnairesEnvironmental healthHBVInternal MedicineHumansMedicineLiver Diseases AlcoholicChronic hepatitisAgedGeographybusiness.industryLiver DiseaseLiver DiseasesHepatitis C ChronicMiddle Agedrespiratory tract diseasesItalyChronic DiseaseHCVChronic hepatitiFemalebusinessAlcoholHuman
researchProduct

Liver cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.

1995

Patients with homozygous protease inhibitor (Pi) type ZZ or a few rare M-like types may develop liver cirrhosis due to intracellular storage of alpha-antitrypsin (AAT), whereas some patients with heterozygous Pi MZ or SZ normally present with transient abnormal liver function tests in childhood. We report a 42-year-old obese patient who developed liver cirrhosis in association with heterozygous Pi MS (AAT) deficiency. Immunohistological and electron microscope examination showed storage of AAT in the hepatocytes. Interestingly, autoimmune features in this patient suggest that abnormal immune responses may contribute to the pathology of chronic liver disease.

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHeterozygoteCirrhosisT-LymphocytesAlpha (ethology)medicine.disease_causeAutoimmunityAutoimmune DiseasesImmunoenzyme TechniquesInternal medicinealpha 1-Antitrypsin DeficiencyPiMedicineHumansProtease inhibitor (pharmacology)ObesityAutoimmune diseaseAlpha 1-antitrypsin deficiencybusiness.industryGastroenterologymedicine.diseaseTrypsin deficiencyFlow CytometryAlcoholismMicroscopy ElectronEndocrinologyPhenotypeLiveralpha 1-AntitrypsinCytokinesbusinessDigestion
researchProduct

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

2019

In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis.We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also c…

AdultLiver CirrhosisMalemedicine.medical_specialtyBiopsydigestive systemGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseBiopsymedicinePrevalenceHumansrisk factorsRisk factorhistory; inflammatory response; progression; risk factorsHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesinflammatory responsemedicine.diseasedigestive system diseasesFatty LiverCross-Sectional StudiesItalyLiver030220 oncology & carcinogenesisLiver biopsyCohort030211 gastroenterology & hepatologyFemalehistoryprogressionSteatohepatitisbusiness
researchProduct

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

2013

Abstract Background Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysisLogistic regressionGastroenterologyCohort StudiesHepatitis B ChronicLiver Cirrhosis AlcoholicRisk FactorsInternal medicinemedicineHumansIn patientAspartate AminotransferasesChemoembolization TherapeuticAdverse effectAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyAcute Kidney InjuryHepatitis C ChronicLiver Failure AcuteMiddle Agedmedicine.diseaseUniversity hospitalTumor BurdenSurgeryLogistic ModelsTreatment OutcomeDoxorubicinHepatic EncephalopathyHepatocellular carcinomaMultivariate AnalysisToxicityFemaleChemical and Drug Induced Liver InjuryIdarubicinbusinessDigestive and Liver Disease
researchProduct

Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis

1996

Cathepsin D serum mass concentrations were determined by enzyme immunoassay in patients with hepatocellular carcinoma (n = 51) and/or liver cirrhosis (n = 92) or benign steatosis (n = 16) and correlated with some biochemical and clinical properties of these diseases. Increased cathepsin D serum mass concentrations (P < 0.001) were observed in all these groups of patients as compared to normal subjects (n = 98). However, patients with steatosis had serum mass concentrations of this enzyme significantly lower (mean 2—3 fold) than those measured in cancer patients (P < 0.05) or cirrhotic patients (P < 0.001). Interestingly, significantly higher cathepsin D serum mass concentrations (m…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularClinical BiochemistryeducationLiver cirrhosis tumor markrersCathepsin DBiologymedicine.disease_causeCathepsin DImmunoenzyme TechniquesInternal medicinemedicineHumansAgedchemistry.chemical_classificationmedicine.diagnostic_testHepatitis AlcoholicBiochemistry (medical)Liver NeoplasmsGeneral Medicinehepatocellular carcinomaMiddle Agedmedicine.diseaseEnzymeEndocrinologychemistryImmunoassayHepatocellular carcinomaFemalealpha-FetoproteinsSteatosisCarcinogenesisLiver function tests
researchProduct

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alco…

2008

Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption. Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake. The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone. Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60]. Protocol biopsies were done in HCV …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationmedicine.disease_causeGastroenterologyBody Mass IndexLiver diseasePostoperative ComplicationsLiver Cirrhosis AlcoholicInternal medicineHumansMedicineAgedTransplantationHepatologybusiness.industryIncidence (epidemiology)Graft Survivalvirus diseasesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinomaEtiologyFemaleSurgerybusinessBody mass indexImmunosuppressive AgentsLiver Transplantation
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease

2019

Background & Aims Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non‐alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron‐overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD. Methods We selected 468 patients with biopsy‐proven NAFLD from 2 European centres. Iron, hepatic and metabolic parameters were collected at the time of liver biopsy. Iron deposits in hepatocytes and reticuloendothelial c…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadBiopsyGastroenterologyhistology03 medical and health sciencesLiver diseaseiron0302 clinical medicineFibrosisInternal medicinemedicineHumansRetrospective StudiesMetabolic SyndromeHepatologymedicine.diagnostic_testbiologybusiness.industryferritinFatty livernon-alcoholic fatty liver diseaseMononuclear phagocyte systemMiddle Agedmedicine.diseaseFerritinLogistic ModelsLiver030220 oncology & carcinogenesisLiver biopsyFerritinsDisease Progressionbiology.proteinFemale030211 gastroenterology & hepatologyAlcoholic fatty liverferritin; histology; iron; non-alcoholic fatty liver diseaseSteatohepatitisbusinessLiver International
researchProduct